Bolt Projects Holdings, Inc. (BSLK) presents a deeply negative liquidation posture as of September 30, 2025. Total assets are $11.1 million against total liabilities of $23.9 million, yielding reported book equity of negative $12.7 million. Under liquidation haircuts, the recovery picture deteriorates further: cash of $4.7 million recovers at par; accounts receivable of $0.2 million at 90-95% is immaterial; inventory of $1.0 million at 60% yields approximately $0.6 million; PP&E of $0.03 million at 50-70% is negligible; other current assets ($1.3 million prepaid/other, $0.4 million deferred costs) and noncurrent assets ($3.4 million, primarily prepaid manufacturing-related) carry minimal to zero liquidation value. Intangibles are zero-carrying but the Vegan Silk Technology Platform IP has no separately stated intangible book value, consistent with the SPAC merger accounting where no goodwill or intangibles were recorded. Gross haircutted asset recovery approximates $6-7 million against $23.9 million of liabilities at face value, implying an estimated liquidation recovery to equity of approximately negative $17 to $18 million, consistent with MFFAIS's CLV/LLV metrics of approximately negative $18.6 to $18.8 million. The dominant liability is the Amended Senior Secured Note to Ginkgo Bioworks with a carrying value (at fair value) of $12.9 million maturing December 31, 2027, plus current liabilities of $10.6 million including $2.9 million excise tax payable (IRC Section 4501), $2.7 million accrued professional fees, and $0.6 million interest payable. The excise tax liability has a proposed IRS payment plan but remains at face value in a liquidation scenario. Quarter-over-quarter, cash improved from $1.0 million at June 30, 2025 to $4.7 million at September 30, 2025, driven by the August 2025 PIPE ($4.25 million gross, $0.6 million in transaction costs) partially offset by operating cash burn of approximately $0.9 million for Q3 alone. The Seneca Transaction extinguished $1.7 million of vendor payables via equity issuance but generated a $3.1 million loss on extinguishment, reflecting that shares issued at market exceeded the payable face value — a dilutive equity-for-liability swap that reduced accounts payable but increased share count by 730,439. The Ascent ELOC ($20 million facility, floor price $1.00/share) is available but untapped as of period end; post-period, four advance notices have drawn $1.8 million gross. Going concern doubt is explicit. The filing discusses the $2.9 million IRS excise tax obligation and the Sponsor Settlement Agreement in MD&A but the excise tax liability is separately tagged as SalesAndExciseTaxPayableCurrent in XBRL. Manufacturing dependency on a single contract manufacturer (Laurus Bio) and the single-customer revenue concentration (one three-year supply agreement generating the preponderance of 2025 revenue of $1.8 million YTD) both represent contingent liabilities not captured on the balance sheet. Multiple material weaknesses in ICFR remain unremediated as of filing date.
▼ Community Notes